LT2585104T - Būdai ir kompozicijos, skirti arilsulfatazės a pristatymui į cns - Google Patents

Būdai ir kompozicijos, skirti arilsulfatazės a pristatymui į cns

Info

Publication number
LT2585104T
LT2585104T LT11799037T LT11799037T LT2585104T LT 2585104 T LT2585104 T LT 2585104T LT 11799037 T LT11799037 T LT 11799037T LT 11799037 T LT11799037 T LT 11799037T LT 2585104 T LT2585104 T LT 2585104T
Authority
LT
Lithuania
Prior art keywords
arylsulfatase
compositions
methods
cns delivery
cns
Prior art date
Application number
LT11799037T
Other languages
English (en)
Inventor
Nazila Salamat-Miller
Katherine Taylor
Paul Campolieto
Zahra Shahrokh
Jing Pan
Lawrence Charnas
Teresa Leah Wright
Pericles Calias
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of LT2585104T publication Critical patent/LT2585104T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
LT11799037T 2010-06-25 2011-06-25 Būdai ir kompozicijos, skirti arilsulfatazės a pristatymui į cns LT2585104T (lt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US35885710P 2010-06-25 2010-06-25
US36078610P 2010-07-01 2010-07-01
US38786210P 2010-09-29 2010-09-29
US201161435710P 2011-01-24 2011-01-24
US201161442115P 2011-02-11 2011-02-11
US201161476210P 2011-04-15 2011-04-15
US201161495268P 2011-06-09 2011-06-09
PCT/US2011/041926 WO2011163650A2 (en) 2010-06-25 2011-06-25 Methods and compositions for cns delivery of arylsulfatase a

Publications (1)

Publication Number Publication Date
LT2585104T true LT2585104T (lt) 2019-10-25

Family

ID=46888844

Family Applications (1)

Application Number Title Priority Date Filing Date
LT11799037T LT2585104T (lt) 2010-06-25 2011-06-25 Būdai ir kompozicijos, skirti arilsulfatazės a pristatymui į cns

Country Status (25)

Country Link
US (1) US9770410B2 (lt)
EP (3) EP3626257B1 (lt)
JP (1) JP6045493B2 (lt)
KR (5) KR102537084B1 (lt)
CN (1) CN103282046B (lt)
AU (4) AU2011270670B2 (lt)
BR (1) BR112012033216B1 (lt)
CA (1) CA2803003C (lt)
CY (2) CY1122282T1 (lt)
DK (1) DK2585104T3 (lt)
ES (1) ES2754776T3 (lt)
HR (1) HRP20191923T1 (lt)
IL (3) IL291556B2 (lt)
LT (1) LT2585104T (lt)
ME (1) ME03647B (lt)
MX (1) MX344795B (lt)
NZ (2) NZ702799A (lt)
PL (2) PL3626257T3 (lt)
RS (1) RS59468B1 (lt)
RU (1) RU2671503C2 (lt)
SI (1) SI2585104T1 (lt)
TW (1) TWI667037B (lt)
UA (1) UA115650C2 (lt)
WO (1) WO2011163650A2 (lt)
ZA (1) ZA201300675B (lt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140005842A (ko) 2010-06-25 2014-01-15 샤이어 휴먼 지네틱 테라피즈 인크. 헤파란 n-설파타제의 cns 전달을 위한 방법들 및 조성물들
HUE046409T2 (hu) 2010-06-25 2020-02-28 Shire Human Genetic Therapies Arilszulfatáz-A központi idegrendszerbe juttatására szolgáló eljárások és készítmények
ES2650689T3 (es) 2010-06-25 2018-01-19 Shire Human Genetic Therapies, Inc. Administración de agentes terapéuticos al sistema nervioso central
EP3626257B1 (en) 2010-06-25 2021-08-04 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of arylsulfatase a
EP3964229A1 (en) 2010-06-25 2022-03-09 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of iduronate-2-sulfatase
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
EP2943568B1 (en) * 2013-01-09 2019-11-20 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
BR112015028605A8 (pt) * 2013-05-15 2019-12-24 Univ Minnesota uso de uma composição e uso de um imunossupressor e uma composição
US10208734B2 (en) * 2015-04-23 2019-02-19 Continuum Dynamics, Inc. Lift-driven wind turbine with force canceling blade configuration
AU2016292759B2 (en) * 2015-07-10 2021-05-20 Byondis B.V. Compositions comprising antibody-duocarmycin drug conjugates
CN108883162A (zh) * 2016-02-17 2018-11-23 夏尔人类遗传性治疗公司 用于芳基硫酸酯酶a的cns递送的方法和组合物
KR102473887B1 (ko) * 2016-06-01 2022-12-06 세르비에 아이피 유케이 리미티드 폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법
CA3048381A1 (en) * 2016-12-28 2018-07-05 Jcr Pharmaceuticals Co., Ltd. Lyophilized preparation
SG11202002457RA (en) 2017-09-22 2020-04-29 Univ Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
CN111699249A (zh) 2017-12-19 2020-09-22 夏尔人类遗传性治疗公司 纯化的芳基硫酸酯酶a及其组合物
CN112566652A (zh) 2018-06-25 2021-03-26 Jcr制药股份有限公司 含有蛋白的水性液体制剂
US20220348981A1 (en) * 2019-09-23 2022-11-03 University Of Washington Assay of arylsulfatase a enzymatic activity in dried blood spots by mass spectrometry and fluorometry

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743265A (en) 1986-04-23 1988-05-10 Dij Catheter Corp Articulated catheter placement device
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
EP0900569B1 (en) 1997-08-22 2002-10-02 Seikagaku Corporation Therapeutic agent for herniated intervertebral disc
KR20010101131A (ko) 1998-12-07 2001-11-14 추후기재 폼페병의 치료 방법
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US20020099025A1 (en) 1999-12-30 2002-07-25 Heywood James A. Treatment of neurological disorders
US6866844B2 (en) 2002-11-07 2005-03-15 Biomarin Pharmaceutical Inc. Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
CA2445577C (en) 2001-04-30 2012-07-03 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
WO2003032727A1 (en) 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
NZ536361A (en) 2002-04-25 2008-05-30 Shire Human Genetic Therapies Treatment of alpha-galactosidase a deficiency
CA2487815A1 (en) 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
ES2371913T3 (es) 2003-01-22 2012-01-11 Duke University Constructos mejorados para expresar polipéptidos lisosomales.
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
JP5624256B2 (ja) 2003-06-20 2014-11-12 ラプター・ファーマシューティカル・インコーポレイテッド 脳および他の組織への治療化合物の送達
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
JP4586027B2 (ja) 2004-01-30 2010-11-24 シャイア ファーマシューティカルズ アイルランド リミテッド 組換えアリールスルファターゼａの製造及び精製
US20060029656A1 (en) 2004-02-03 2006-02-09 Biodelivery Sciences International, Inc. Replacement enzyme cochleates
BRPI0507440A (pt) 2004-02-06 2007-07-10 Biomarin Pharm Inc fabricação de enzimas lisossomais altamente fosforiladas e uso das mesmas
WO2005078077A2 (en) 2004-02-10 2005-08-25 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20050208090A1 (en) 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
US20090297592A1 (en) 2005-05-11 2009-12-03 Jcr Pharmaceuticals Co., Ltd. Lipid Vesicle Composition
US7964617B2 (en) 2005-06-08 2011-06-21 Amicus Therapeutics, Inc. Methods for treating parkinsons disease and parkinsonism
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
EP2628746B1 (en) * 2006-04-04 2019-01-09 Chiesi Farmaceutici S.p.A. A process for the concentration of a polypeptide
CN101410408A (zh) * 2006-04-04 2009-04-15 希尔制药爱尔兰有限责任公司 用于浓缩多肽的方法
GB0611463D0 (en) 2006-06-09 2006-07-19 Novartis Ag Organic compounds
US8419710B2 (en) 2006-12-06 2013-04-16 Medtronic, Inc. Methods for infusing fluids via an implantable infusion system
CA2680189A1 (en) 2007-03-06 2008-09-12 Saint Louis University Modified enzyme and treatment method
EP2185701A4 (en) 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
WO2009073569A2 (en) 2007-11-30 2009-06-11 Abbott Laboratories Protein formulations and methods of making same
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
BRPI0912225A2 (pt) 2008-05-07 2018-03-20 Zystor Therapeutics, Inc. peptídeos de direcionamento lisossomais e usos dos mesmos
US8436489B2 (en) 2009-06-29 2013-05-07 Lightsail Energy, Inc. Compressed air energy storage system utilizing two-phase flow to facilitate heat exchange
EP3626257B1 (en) 2010-06-25 2021-08-04 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of arylsulfatase a
JP6063380B2 (ja) 2010-06-25 2017-01-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド サンフィリポ症候群ｂ型の処置
WO2011163651A2 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. METHODS AND COMPOSITIONS FOR CNS DELIVERY OF β-GALACTOCEREBROSIDASE
ES2650689T3 (es) 2010-06-25 2018-01-19 Shire Human Genetic Therapies, Inc. Administración de agentes terapéuticos al sistema nervioso central
HUE046409T2 (hu) 2010-06-25 2020-02-28 Shire Human Genetic Therapies Arilszulfatáz-A központi idegrendszerbe juttatására szolgáló eljárások és készítmények
EP3964229A1 (en) 2010-06-25 2022-03-09 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of iduronate-2-sulfatase
KR20140005842A (ko) 2010-06-25 2014-01-15 샤이어 휴먼 지네틱 테라피즈 인크. 헤파란 n-설파타제의 cns 전달을 위한 방법들 및 조성물들
JP2012062312A (ja) 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤

Also Published As

Publication number Publication date
NZ605873A (en) 2015-02-27
KR102537084B1 (ko) 2023-05-26
AU2021236557A1 (en) 2021-10-28
KR20180059580A (ko) 2018-06-04
JP6045493B2 (ja) 2016-12-14
HRP20191923T1 (hr) 2020-01-10
AU2017202289A1 (en) 2017-04-27
KR102318997B1 (ko) 2021-10-29
KR20130135821A (ko) 2013-12-11
EP2585104A4 (en) 2014-01-15
KR102094094B1 (ko) 2020-03-27
RU2671503C2 (ru) 2018-11-01
WO2011163650A2 (en) 2011-12-29
PL2585104T3 (pl) 2020-01-31
AU2019204051B2 (en) 2021-07-22
AU2019204051A1 (en) 2019-08-29
KR20200035167A (ko) 2020-04-01
AU2017202289B2 (en) 2019-03-14
TW201206464A (en) 2012-02-16
CA2803003C (en) 2022-11-22
KR20230079472A (ko) 2023-06-07
RU2012154574A (ru) 2014-07-27
RS59468B1 (sr) 2019-11-29
MX2013000323A (es) 2013-06-05
KR20210131449A (ko) 2021-11-02
PL3626257T3 (pl) 2022-03-28
BR112012033216B1 (pt) 2022-10-11
IL291556B2 (en) 2024-02-01
WO2011163650A3 (en) 2013-06-13
US9770410B2 (en) 2017-09-26
EP3626257A1 (en) 2020-03-25
KR101997935B1 (ko) 2019-10-04
AU2011270670B2 (en) 2017-01-12
IL273854B (en) 2022-04-01
IL273854A (en) 2020-05-31
MX344795B (es) 2017-01-05
SI2585104T1 (sl) 2019-11-29
EP3626257B1 (en) 2021-08-04
JP2013538788A (ja) 2013-10-17
DK2585104T3 (da) 2019-10-14
NZ702799A (en) 2016-08-26
US20120009171A1 (en) 2012-01-12
IL223758B (en) 2020-04-30
BR112012033216A2 (pt) 2020-08-25
ZA201300675B (en) 2017-11-29
CY1124910T1 (el) 2023-01-05
IL291556B1 (en) 2023-10-01
UA115650C2 (uk) 2017-12-11
EP2585104B1 (en) 2019-08-21
CY1122282T1 (el) 2020-11-25
EP3964230A1 (en) 2022-03-09
TWI667037B (zh) 2019-08-01
IL291556A (en) 2022-05-01
CN103282046A (zh) 2013-09-04
CA2803003A1 (en) 2011-12-29
EP2585104A2 (en) 2013-05-01
AU2011270670A1 (en) 2013-02-14
ES2754776T3 (es) 2020-04-20
ME03647B (me) 2020-07-20
CN103282046B (zh) 2015-05-13

Similar Documents

Publication Publication Date Title
IL291556A (en) Methods and preparations for administration of arylsulfatase a to the central nervous system
HK1214149A1 (zh) 芳基硫酸酯酶 遞送的方法和組合物
IL284599A (en) Methods and preparations for administration of iduronate-2-sulfatase to the central nervous system
EP2588131A4 (en) METHODS AND COMPOSITIONS FOR CNS ADMINISTRATION OF HEPARAN N-SULFATASE
EP2558120A4 (en) METHOD AND COMPOSITION FOR INTRANASAL ADMINISTRATION
EP2408435A4 (en) COMPOSITIONS AND METHODS FOR DELIVERING AGENT TO A WOUND
EP2624702A4 (en) ANTI-BIOFILM COMPOSITIONS AND METHODS OF USE
EP2588132A4 (en) METHOD AND COMPOSITIONS FOR DELIVERING BETA GALACTOCEREBROSIDASE INTO THE CNS
EP2555788A4 (en) METHOD AND COMPOSITIONS FOR THE PROTECTION AND REGENERATION OF THE HEART
EP2793922A4 (en) STABLE FORMULATIONS FOR THE ADMINISTRATION OF ARYLSULFATASE A IN THE CNS
EP2558863A4 (en) COMPOSITIONS AND METHODS FOR CHARACTERIZING MYOPATHY
EP2440192A4 (en) COMPOSITIONS AND METHODS FOR ADMINISTERING MATERIALS
EP2437735A4 (en) COMPOSITIONS AND METHODS FOR ADMINISTERING SUBSTANCES